Pharmaceuticals

Akanda

Akanda released FY2025 Q2 earnings on October 1, 2025 (EST) with actual revenue of USD 0 and EPS of USD -0.5872

Akanda released FY2025 Semi-Annual earnings on October 1, 2025 (EST), with actual revenue of USD 0 and EPS of USD -1.1745

Akanda released FY2025 Q1 earnings on October 1, 2025, EST: Actual Revenue USD 0, Actual EPS USD -0.5872

First Towers & Fiber Corp. Expanding Role in Mexico's Telecommunications Project

Akanda released FY2024 Q3 earnings on April 30 (EST), actual revenue USD 179.83 K, actual EPS USD -0.4383

Akanda released FY2024 9 Months earnings on April 30 (EST), actual revenue USD 179.83 K, actual EPS USD -19.1293

Akanda released FY2024 Q4 earnings on April 30 (EST), actual revenue USD 179.83K, actual EPS USD -1.3697

Akanda released FY2024 Annual Earnings on April 30 (EST), actual revenue USD 836.66K, actual EPS USD -12.284

Akanda released FY2024 Q2 earnings on October 30 (EST), actual revenue USD 0, actual EPS USD -8.8798

Akanda released FY2024 Q1 earnings on October 30 (EST), with actual revenue of 238.5 K USD and EPS of -2.8415 USD

Akanda released FY2024 Semi-Annual earnings on October 30 (EST), actual revenue USD 0, actual EPS USD -17.7596

Akanda released FY2023 Q3 earnings on May 1, 2024 (EST) with actual revenue of USD 147.47 K and EPS of USD -662.4138

Akanda released FY2023 Q4 earnings on May 1, 2024 (EST), actual revenue USD 147.47 K, actual EPS USD -662.4138

Akanda released FY2023 9 Months earnings on May 1, 2024 (EST), actual revenue USD 276.21 K, actual EPS USD -1.027 K

Akanda released FY2023 Annual Earnings on May 1, 2024 (EST), with actual revenue of USD 423.68K and EPS of USD -1.791K

Akanda released FY2022 Q2 earnings on December 29 (EST), actual revenue USD 36.55K, actual EPS USD -120.819

Akanda released FY2023 Q2 earnings on December 29 (EST), actual revenue USD 64.37K, actual EPS USD -182.3503

Akanda released FY2023 Q1 earnings on December 29 (EST), actual revenue USD 64.37K, actual EPS USD -182.3503

Akanda released FY2022 Q1 earnings on December 29, 2023 (EST), with actual revenue of USD 36.55K and EPS of USD -120.819

Akanda released FY2023 Semi-Annual earnings on December 29 (EST), actual revenue USD 128.74 K, actual EPS USD -364.7007

Top Wealth

Orangekloud Tech

Wave Life Sciences

Cemtrex

Webuy Global

Structure Therapeutics

Biodexa Pharmaceuticals

Creative Media & Community Trust

Fulcrum Therapeutics

Kymera Therapeutics

礼来

罗氏(ADR)

ROCHE HOLDINGS AG

阿斯利康

诺华制药

诺和诺德公司

中外制药(ADR)

UCB(ADR)

第一三共株式会社(ADR)

大冢制药(ADR)

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap